OncoCyte Corp (OCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OncoCyte Corp (OCX) has a cash flow conversion efficiency ratio of -0.573x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($10.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OncoCyte Corp stock valuation for the company's overall valuation and market capitalisation.
OncoCyte Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how OncoCyte Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OncoCyte Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OncoCyte Corp ranked by their cash flow conversion efficiency. Explore OncoCyte Corp (OCX) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raute Oyj
HE:RAUTE
|
-0.095x |
|
Fullerton Technology Co Ltd
TW:6136
|
0.007x |
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IS:YATAS
|
0.116x |
|
First US Bancshares Inc
NASDAQ:FUSB
|
0.007x |
|
DENARIUS METALS CORP.
F:T7C0
|
-0.039x |
|
Applied BioCode
TW:6598
|
-0.029x |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
0.063x |
|
Adese Gayrimenkul Yatirim AS
IS:ADESE
|
-0.008x |
Annual Cash Flow Conversion Efficiency for OncoCyte Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of OncoCyte Corp from 2013 to 2024. View latest OncoCyte Corp stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.27 Million | $-20.71 Million | 1.688x | +285.17% |
| 2023-12-31 | $25.59 Million | $-23.32 Million | -0.911x | +31.42% |
| 2022-12-31 | $34.29 Million | $-45.57 Million | -1.329x | -141.12% |
| 2021-12-31 | $65.22 Million | $-35.94 Million | -0.551x | +28.97% |
| 2020-12-31 | $33.48 Million | $-25.98 Million | -0.776x | -21.37% |
| 2019-12-31 | $30.84 Million | $-19.71 Million | -0.639x | +81.21% |
| 2018-12-31 | $3.42 Million | $-11.65 Million | -3.403x | -11.95% |
| 2017-12-31 | $4.40 Million | $-13.38 Million | -3.040x | -298.57% |
| 2016-12-31 | $9.86 Million | $-7.52 Million | -0.763x | -87.88% |
| 2015-12-31 | $10.42 Million | $-4.23 Million | -0.406x | -137.46% |
| 2014-12-31 | $-1.07 Million | $-1.16 Million | 1.084x | +651.82% |
| 2013-12-31 | $3.62 Million | $-710.00K | -0.196x | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more